Systemic Therapy Treatment Plan (Chemotherapy/Immunotherapy)

Patient Name: [Patient Name]

MRN: [Medical Record Number]

DOB: [Date of Birth]

Note Date: [Date]

Author/Role: [Clinician name and credentials]

Encounter Type: [clinic / telehealth / inpatient consult]

Planned Treatment Location: [infusion center / home / oral]

Regimen Status: [New regimen / Continuation / Modification of prior regimen]

Allergies/Hypersensitivity: [All drug allergies and prior infusion reactions; if none known, state "No known drug allergies" and "No prior infusion reactions"]

Safety Flags: [Central venous access status, pregnancy risk/screening status, infection precautions as applicable]

(Use this template for initiating a new regimen, restarting after prolonged interruption, or substantive regimen changes. Do not use for routine administration documentation, surveillance-only visits, or minor dose adjustments.)

Regimen at a Glance

(Present as a compact block for rapid verification.)

Diagnosis/Status: [Primary diagnosis with histology and stage or disease status]
Line of Therapy: [1L / 2L / 3L+ / Adjuvant / Neoadjuvant / Maintenance]
Treatment Intent: [curative / disease control / palliative]
Regimen: [Regimen name with acronym spelled out]
Cycle: [Cycle length in days]; Planned Duration: [Number of cycles or stop criteria]
Supportive Care: [Antiemetic risk category: minimal / low / moderate / high]; [Growth factor: none / primary prophylaxis / secondary prophylaxis]
Planned Response Assessment: [Criteria and timeframe for first reevaluation]

Clinical Context

[Cancer diagnosis: primary site, histology, grade, staging system, clinical vs pathologic stage, current disease status, sites of measurable disease] (Reference prior notes for full history.)

[Actionable biomarkers and molecular testing relevant to therapy selection or monitoring with test name, result, and date]

[Prior systemic therapies: regimen names, dates, best response, and reason for discontinuation] (Include for patients beyond first-line therapy.)

[Pending confirmations with decision owner and expected date] (State explicitly if staging or line of therapy awaiting confirmation.)

Baseline Assessment

• [Performance status (ECOG or Karnofsky) with assessment date]
• [Height, weight with measurement dates, calculated BSA, dosing metric used] (Use leading zeros for doses less than 1 mg; avoid trailing zeros.)
• [Renal function with calculation method if dosing-relevant; hepatic function summary if relevant]
• [Key comorbidities and baseline organ function affecting regimen choice or dosing]
• [Medication reconciliation status including OTC and herbals; interaction risks and actions taken]
• [Baseline autoimmune disease history, chronic infection status, and baseline endocrine function] (Include for immunotherapy regimens only.)
• [Required baseline tests: completed vs pending with expected completion date] (Do not infer absence of conditions; if history unknown, state explicitly.)

Regimen Specification

Order Set/Protocol: [Institutional order set name or protocol reference]

Planned Start: [Start date or criteria to start]

• Antineoplastic Agents (List each agent separately.)
  • [Agent 1: generic name]: [Route], [Dose basis], [Calculated dose for this patient], [Schedule by cycle day], [Infusion duration if applicable]
  • [Agent 2: generic name]: [Route], [Dose basis], [Calculated dose for this patient], [Schedule by cycle day], [Infusion duration if applicable]
  • (Add additional agents as needed.)
• Premedications: [Drug, dose, route, timing relative to infusion; hypersensitivity prophylaxis if applicable]
• Hydration: [Pre-/post-hydration fluid, volume, rate, timing; urine output targets if applicable] (Include for nephrotoxic agents.)
• Oral Agent Instructions: [Exact dosing with strength and frequency, quantity, start date, missed-dose guidance, adherence monitoring plan] (Include only if regimen contains oral therapy.)
• Criteria to Treat / Hold / Modify: [Minimum lab thresholds to proceed; toxicity grades requiring hold or dose reduction; dose modification schema with rationale if pre-planned]

Supportive Care and Monitoring

• Antiemetic Prophylaxis: [Risk category-matched plan with drugs, doses, and schedule]
• Infection Prophylaxis: [Growth factor plan; PJP, antiviral, and antifungal prophylaxis as indicated]
• HBV Screening/Management: [HBsAg, anti-HBc, anti-HBs status; prophylaxis or monitoring plan if indicated]
• Monitoring Schedule: [Visit cadence; labs with timing; on-treatment assessment schedule]
• Imaging/Response Assessment: [Modality, criteria, and timing of first and subsequent reevaluations]
• Immune-Related Monitoring: [Thyroid function cadence; irAE escalation plan; symptoms requiring urgent contact; where to present] (Include for immunotherapy regimens only.)
• Decision Triggers: [Criteria to continue, modify, hold, or discontinue therapy]

Education, Consent, and Plan Status

• [Patient education provided: diagnosis, treatment goals, drugs and schedule, expected toxicities, urgent symptoms, and 24/7 contact process]
• [Informed consent status and storage location]
• [Education on oral therapy handling, administration, storage, and disposal confirmed] (Include for oral therapy regimens.)
• [PCP notification plan and ED letter availability]
• [Pregnancy screening status; fertility preservation discussion; contraception counseling] (Include if applicable.)
• [Psychosocial screening results and plan to address barriers] (Include if barriers identified.)
• [Plan reviewed with patient/caregiver; questions answered]
• Readiness State: [Draft / Ready for Ordering / Ready for Treatment Start] (If required elements are pending, mark as Draft and list outstanding items with expected dates.)